MARLBOROUGH, Mass.,
July 20, 2015 /PRNewswire/
-- Boston Scientific (NYSE: BSX) has initiated a study of the
company's first fully resorbable drug-eluting scaffold system. The
Fully Absorbable Scaffold Feasibility Study (FAST) is a
prospective, single arm study designed to assess the safety and
performance of this next generation scaffold for the treatment of
atherosclerotic coronary lesions.
The first patients in the study were enrolled by Professor
Ian Meredith, primary investigator
and director of MonashHeart, at Monash Medical Centre in
Melbourne, Australia. The study
will enroll up to 30 patients.
"By virtue of its unique design properties, incorporating
thinner struts and enabling greater stent expansion while
maintaining radial strength, this fully resorbable scaffold
technology may potentially overcome a number of limitations with
first generation absorbable scaffolds," said Professor
Meredith.
The resorbable polymer scaffold incorporates several key design
elements from the Boston Scientific SYNERGY™ Stent System,
including a resorbable polymer and an ultrathin everolimus coating
which is applied abluminally (on the exterior) to the scaffold. It
also features a delivery system built with Boston Scientific
expertise designed to facilitate improved acute performance.
"We are taking the best of our SYNERGY stent and applying it to
our new, fully resorbable scaffold technology," said Kevin Ballinger, president, Interventional
Cardiology, Boston Scientific. "We continue to invest in meaningful
innovations designed to provide better outcomes for patients with
coronary artery disease."
The Boston Scientific fully resorbable scaffold technology is
under development and is not available for sale. The SYNERGY
Stent is an investigational device in the U.S. and Japan, and is not available for sale in those
countries. The SYNERGY Stent has CE mark approval and is available
for sale in countries where CE mark is accepted.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding our products, our
business plans, clinical trials, and product performance. If our
underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some
cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS
Media: Ryan Davenport
Global Media Relations
Boston Scientific Corporation
763-494-2664 (office)
media@bsci.com
Investors: Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-initiates-study-evaluating-new-fully-resorbable-scaffold-technology-300115151.html
SOURCE Boston Scientific